These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12710216)

  • 21. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
    Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor effect of cotylenin A plus interferon-alpha: possible therapeutic agents against ovary carcinoma.
    Honma Y; Kasukabe T; Yamori T; Kato N; Sassa T
    Gynecol Oncol; 2005 Dec; 99(3):680-8. PubMed ID: 16112179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer.
    Dai D; Holmes AM; Nguyen T; Davies S; Theele DP; Verschraegen C; Leslie KK
    Cancer Res; 2005 Oct; 65(20):9517-24. PubMed ID: 16230417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiogenesis. A boost for tumor starvation.
    Marx J
    Science; 2003 Jul; 301(5632):452-4. PubMed ID: 12881543
    [No Abstract]   [Full Text] [Related]  

  • 26. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent.
    Rebbaa A; Chu F; Davis FB; Davis PJ; Mousa SA
    Angiogenesis; 2008; 11(3):269-76. PubMed ID: 18386142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo.
    Radfar S; Wang Y; Khong HT
    J Immunol; 2009 Nov; 183(10):6800-7. PubMed ID: 19846868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance.
    Fu L; Liang Y; Deng L; Ding Y; Chen L; Ye Y; Yang X; Pan Q
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):349-56. PubMed ID: 14666379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma.
    Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Bhanot U; Hasel C; Möller P; Gschwend JE; Simmet T; Debatin KM; Fulda S
    Cancer Res; 2009 Mar; 69(6):2425-34. PubMed ID: 19258513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer.
    Han GZ; Liu ZJ; Shimoi K; Zhu BT
    Cancer Res; 2005 Jan; 65(2):387-93. PubMed ID: 15695378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
    Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
    Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The outlook for the use of antioxidants in the combined treatment of malignant tumors].
    Sukolinskiĭ VN
    Vopr Onkol; 1990; 36(2):138-44. PubMed ID: 2180207
    [No Abstract]   [Full Text] [Related]  

  • 35. Minicells mitigate tumor growth.
    Dorans K
    Lab Anim (NY); 2009 Aug; 38(8):250. PubMed ID: 19626008
    [No Abstract]   [Full Text] [Related]  

  • 36. 1-(3-C-Ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106), a novel potent inhibitor of RNA polymerase, potentiates the cytotoxicity of CDDP in human cancer cells both in vitro and in vivo.
    Kazuno H; Fujioka A; Fukushima M; Wataya Y; Matsuda A; Sasaki T
    Int J Oncol; 2009 May; 34(5):1373-80. PubMed ID: 19360349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
    Hoffman RM
    Methods Mol Med; 2005; 111():297-322. PubMed ID: 15911987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interactions of chemotherapy and radiation.
    Vokes EE
    Semin Oncol; 1993 Feb; 20(1):70-9. PubMed ID: 8475412
    [No Abstract]   [Full Text] [Related]  

  • 39. Porphyrin-cyclodextrin conjugates as a nanosystem for versatile drug delivery and multimodal cancer therapy.
    Králová J; Kejík Z; Bríza T; Poucková P; Král A; Martásek P; Král V
    J Med Chem; 2010 Jan; 53(1):128-38. PubMed ID: 19950899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Angiogenesis as a target for antitumor actions].
    Ushmorov AG; Aleksandrov VA
    Vopr Onkol; 1989; 35(3):263-70. PubMed ID: 2468258
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.